1 3 Right To Experimental Drugs Marycruz Garcia-Jaramillo Capella University PHI3200: Ethics

1

3

Right To Experimental Drugs

Marycruz Garcia-Jaramillo
Capella University
PHI3200: Ethics in Health Care
Instructor: Kim Carter-Cram
April, 2022

Right To Experimental Drugs

Patients with no other treatment plan have a right to use experimental drugs. Experimental drugs are medical and healthcare substances that have been tested in scientific laboratories and proven safe for human testing (Sibanda, 2019). Nurses, doctors, and other medical and healthcare practitioners ensure that all public members have the right to such drugs.  All individuals have a right to experimental drugs because it is the role of the healthcare system to sustain ethical practices by demonstrating uniform and equitable distribution of experimental drugs to all public fraternities.

The right to experimental drugs poses severe complications and requires a comprehensive understanding of the required circumstances under which it applies suitably. Every person needs to be consulted before being subjected to experimental drugs under exceptional circumstances that compel them. An example is when the medical intervention concerning such patients is investigational and requires newly experimental medicines that have been approved and testified by the approved laboratories (Borovecki et al., 2018). Despite having been testified and deemed to have passed all the tests for human treatment, the application of experimental drugs needs to be disseminated to the patient in agreement with the informed consent. Informed consent is how patients get informed before being subjected to experimental drugs (Borovecki et al., 2018). The medical and healthcare practice is a sensitive practice that needs to operate in an ethical and legal jurisprudence by ensuring a close and elaborate communication with a patient before demonstrating any healthcare process.

The right to experimental drugs is equally universal to all. For instance, the application of such drugs needs to be disseminated under exceptional circumstances where the approved drugs have proved to be defective or substandard for patients (Borovecki et al., 2018). Such medicines also need to have cost-benefit implications such that they exhibit relatively fewer expenses to acquire and are more effective in their treatment interventions compared to the approved conventional drugs. However, the World Health Organization (WHO) reiterated that such obligatory interventions need to be handled in an ethical and moral justice by seeking dignity and patient autonomy before demonstrating any aspect of medical and healthcare intervention to them (Borovecki et al., 2018). Based on this critique, WHO implied that all the patients have an equal opportunity to any medical and healthcare treatment intervention, including those drugs that have not yet been tested and approved by the healthcare organizations. Informed consent and patient consultation are ethical practices requiring medical and healthcare practitioners to respect the patient’s autonomy by informing them concerning the drugs’ approval state before injecting them into their bodies (Borovecki et al., 2018). Patients need to make their individual personal decision concerning whether to accept the pills or not.

Despite projecting informed consent to the patients, the medical and the healthcare practitioners need to demonstrate a vital aspect of sound ethical thinking regarding such drugs to avoid getting into the unethical, immoral, and illegal practices that may render their medical and healthcare practices unlawful. Despite having an equal opportunity for the administration of experimental drugs, the doctors, nurses, and all other healthcare workers need to examine the public implications and define the rationale of how the dissemination of experimental medications will impact the social justice of the community (Dagron et al., 2020).  Here, the medical and healthcare systems need to demonstrate a balanced framework because they are liable to different aspects of healthcare professional practice if they fail to comply with the ethical principles stipulated in their professional practice. For instance, they need to consider the equity, social justice, protection of the public health, respect for the informed consent of a patient and foster the values underpinning the healthcare practice by practicing the doctrines that evaluate the welfare of case CU/EA.

Some diseases like covid-19 and the Ebola pandemic impacted the world at the serious crossroad of developing many experimental drugs that saved the world from massive deaths by people. Throughout the application of experimental drugs concerning the above-mentioned global pandemics, informed consent was operational. Patients whose moral and cultural positions coincided with experimental drugs in the case of Ebola and Covid-19 were pardoned to apply the alternative healthcare treatment interventions (Mahant, 2020). Using experimental drugs effectively enabled the world to eradicate Ebola and the late covid-19 pandemic. Based on this argument, there are essential incidences where experimental drugs are effective compared to the proven ones. In such cases, the medical and healthcare systems need to follow the required projections in distributing them to patients, like engaging the patient and respecting their informative understanding of the treatment process through informed consent (Mahant, 2020). Human rights are universal and equally distributive; thus, it is the professional accountability of the medical and healthcare workers to demonstrate their treatment interventions in a legal, ethical, and morally right, even to the public.

Since all people have a right to experimental drugs, healthcare professionals need to ensure equitable dissemination of the drugs to all public fraternities. Besides, patients with no other treatment plan have a right to use experimental drugs. Some illnesses, such as covid-19 and the Ebola outbreak, pushed the globe to the brink of inventing a slew of experimental treatments that rescued the world from mass human fatalities. Because it is the job of healthcare to uphold healthcare ethics by displaying uniform and equal distribution of experimental pharmaceuticals to the general population, everyone has a right to them.

References

Borovecki, A., Mlinaric, A., Horvat, M., & Supak Smolcic, V. (2018). Informed consent and

     ethics committee approval in laboratory medicine. Biochemia Medica, 28(3), 373-382. DOI: 10.11613/BM.2018.030201

Dagron, S., Chakhaia, T., González-Angulo, L., Hermanns, S., Skrahina, A., & Wallace, A. E.M. (2020). Access to experimental medicines for TB: ethical and human rights considerations. The International Journal of Tuberculosis and Lung Disease, 24(5), 38-43. DOI: 10.5588/ijtld.18.0885 Retrieved April, 2022 https://www.ingentaconnect.com/content/iuatld/ijtld/2020/00000024/a00105s1/art00008

Mahant, V. (2020). “Right-to-Try” experimental drugs: an overview. Journal of Translational  Medicine, 18(1), 1-6. DOI: 10.1186/s12967-020-02427-4

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7309195/

Sibanda, O. S. (2019). Moral, ethical, and human rights arguments for using experimental and clinically unproven drugs to combat the Ebola virus. Journal for Juridical Science, 44(1), 35-62. https://doi.org/10.18820/24150517/JJS44.i1.2